Table 1.
Demographics and HSCT characteristics
| Total subjects, N | Donor-derived VST, n | Third-party VST, n | |
|---|---|---|---|
| Male | 25 | 12 | 13 |
| Female | 13 | 6 | 7 |
| Age at transplant, median (range), y | 14.6 (4.7-71) | 17 (6.8-73) | |
| Race | |||
| White | 34 | 16 | 18 |
| African American | 2 | 2 | 0 |
| Asian | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
| Diagnosis category | |||
| Malignancy | 15 | 3 | 12 |
| Immune deficiency | 8 | 4 | 4 |
| Marrow failure | 10 | 9 | 1 |
| Benign hematology | 5 | 2 | 3 |
| Stem cell donor type | |||
| Related (MRD, MMRD, haploidentical) | 5 | 2 | 3 |
| Unrelated (MUD, MMUD) | 33 | 16 | 17 |
| Degree of HLA match | |||
| 12/12 | 7 | 4 | 3 |
| 10/10 | 17 | 8 | 9 |
| 9/10 | 8 | 3 | 5 |
| 5/10 | 6 | 3 | 3 |
| Stem cell source | |||
| Bone marrow (BM or BM-RI) | 16 | 6 | 10 |
| Peripheral blood (PBSC) | 20 | 11 | 9 |
| Cord blood (cord) | 2 | 1 | 1 |
| Conditioning regimen | |||
| Myeloablative | 23 | 10 | 13 |
| Reduced intensity | 15 | 8 | 7 |
| GVHD prophylaxis (allo-HSCT only) | |||
| Calcineurin (CSA, tacrolimus) | 22 | 9 | 13 |
| Other (sirolimus + others) | 8 | 2 | 6 |
| Ex vivo T-cell depletion (CD34 selection) | 8 | 7 | 1 |
| ATG | 3 | 3 | 0 |
CSA, cyclosporine; MMRD, mismatched related donor; MRD, matched related donor; MMUD, mismatched unrelated donor; MUD, matched unrelated donor.